on Hengrui Pharma
Hengrui Showcases Innovation at ESMO 2025
At the 2025 Annual Congress of the European Society for Medical Oncology (ESMO) in Berlin, Hengrui Pharma highlighted its continued commitment to oncology breakthroughs. Hengrui marked a significant milestone by debuting as an exhibitor, demonstrating its growing influence in the global academic community.
Since 2016, Hengrui has consistently participated in ESMO, and this year it unveiled 46 studies across 14 innovative therapeutic programs. Among these were nine oral presentations and four late-breaking abstracts, which underscore the firm's strength in oncology research.
The company hosted various academic events aimed at facilitating dialogue with global experts. Ms. Jo Feng, leading the delegation, emphasized Hengrui's dedication to innovation and patient-centric advancements in medical research.
Hengrui's commitment lies in addressing unmet patient needs through its global R&D network, striving to provide new treatment options worldwide.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Hengrui Pharma news